DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Eluxadolineis the generic ingredient in one branded drug marketed by Allergan Holdings and is included in one NDA. There are fourteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Eluxadoline has one hundred and forty-eight patent family members in thirty-nine countries.
There are two drug master file entries for eluxadoline. One supplier is listed for this compound.
Summary for ELUXADOLINE
|Drug Master File Entries:||2|
|Suppliers / Packagers:||1|
|Bulk Api Vendors:||25|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for ELUXADOLINE|
|DailyMed Link:||ELUXADOLINE at DailyMed|
Recent Clinical Trials for ELUXADOLINE
Identify potential brand extensions & 505(b)(2) entrants
|Temple University||Phase 2/Phase 3|
|University of North Carolina, Chapel Hill||Phase 2|
Pharmacology for ELUXADOLINE
|Drug Class||mu-Opioid Receptor Agonist |
|Mechanism of Action||Opioid mu-Receptor Agonists |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|Allergan Holdings||VIBERZI||eluxadoline||TABLET;ORAL||206940-002||May 27, 2015||RX||Yes||Yes||Start Trial||Start Trial||Start Trial|
|Allergan Holdings||VIBERZI||eluxadoline||TABLET;ORAL||206940-002||May 27, 2015||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Allergan Holdings||VIBERZI||eluxadoline||TABLET;ORAL||206940-001||May 27, 2015||RX||Yes||No||Start Trial||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Exclusivity Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1725537||300865||Netherlands||Start Trial||PRODUCT NAME: ELUXADOLINE OF EEN FARMACEUTISCH AANVAARDBAAR ENANTIOMEER,DIASTEREOMEER, RACEMAAT OF ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/16/1126 20160921|
|1725537||132017000028006||Italy||Start Trial||PRODUCT NAME: ELUXADOLINE O UN ENANTIOMERO, DIASTEREOMERO, RACEMATO FARMACEUTICAMENTE ACCETTABILE O SALI DELLO STESSO(TRUBERZI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1126, 20160921|
|1725537||CR 2017 00008||Denmark||Start Trial||PRODUCT NAME: ELUXADOLIN ELLER EN FARMACEUTISK ACCEPTABEL ENANTIOMER, DIASTEREOMER, RACEMAT ELLER SALT DERAF; REG. NO/DATE: EU/1/16/1126 20160921|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.